Thomas Eastling's most recent trade in Gyre Therapeutics Inc was a trade of 95,060 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gyre Therapeutics Inc | Thomas Eastling | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 95,060 | 95,060 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 95,060 | 95,060 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 92,683 | 92,683 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 47,530 | 47,530 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 33,271 | 33,271 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 33,271 | 33,271 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2026 | 11,882 | 11,882 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.93 per share. | 16 Apr 2025 | 15,000 | 15,000 | - | 6.9 | 103,950 | Common Stock |
| Gyre Therapeutics Inc | Thomas Eastling | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2025 | 15,000 | 299,652 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | Thomas Eastling | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2024 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) |